Ironwood Pharmaceuticals, Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. The filing also presents unaudited fourth-quarter results. Ironwood is a gastrointestinal therapeutics company whose business and revenue are heavily dependent on LINZESS (linaclotide), commercialized in the U.S. through its 50/50 collaboration with AbbVie.
Financial performance and position
| Metric | 2022 | 2021 | Change / context |
|---|---|---|---|
| Total revenue | $410.6 million | $413.8 million | Down 0.8%; principally lower U.S. collaboration revenue and no API sales in 2022. |
| U.S. LINZESS collaboration revenue | $398.8 million | $400.4 million | Down slightly; net price erosion and channel inventory fluctuations were partly offset by higher prescription demand. |
| Operating income | $250.3 million | $232.3 million | Up 7.8%; lower R&D expense was the main driver. Operating margin was approximately 61% versus 56%. |
| Net income | $175.1 million | $528.4 million | Down 66.9%; 2021 included a $333.3 million non-cash tax benefit from releasing most of the deferred-tax valuation allowance. |
| Operating cash flow | $273.8 million | $261.9 million | Up 4.5%. |
| Cash and cash equivalents | $656.2 million | $620.1 million | Unrestricted cash at year-end 2022. |
| Convertible debt | $400.0 million principal; $396.3 million carrying value | $400.0 million principal remaining at year-end | 2022 notes of $120.7 million were repaid at maturity; remaining $200 million notes mature in 2024 and $200 million in 2026. |
Year-end current assets were $780.6 million and current liabilities were $25.5 million. Total assets were $1.10 billion and stockholders’ equity was $652.4 million. The company repurchased 10.8 million shares for $123.4 million during 2022 and completed its $150 million repurchase authorization. No cash dividends have been paid, and none are anticipated in the foreseeable future.
Fourth quarter: Revenue was $107.2 million and net income was $48.9 million, compared with $117.1 million and $41.4 million, respectively, in Q4 2021. Q4 2022 total costs and expenses were $38.8 million.
Material changes versus the prior comparable period
- Revenue was broadly stable, while operating income improved as R&D expense fell to $44.3 million from $70.4 million. The decrease largely reflected lower COUR-related payments and reduced IW-3718 and linaclotide development costs; IW-3300 development spending increased.
- Interest expense declined to $7.6 million from $31.2 million, mainly because adoption of ASU 2020-06 reduced non-cash interest expense and the 2022 notes were repaid in June.
- Income tax changed from a $327.8 million benefit in 2021 to a $77.4 million expense in 2022, primarily non-cash. The 2021 benefit followed release of most of the valuation allowance on deferred tax assets.
- The company adopted ASU 2020-06 using the modified retrospective method, changing convertible-note accounting and reducing reported non-cash interest expense; the adoption did not affect liquidity or cash flows.
Outlook, commentary, risks and unusual items
- Management said year-end cash and expected operating inflows should meet projected operating needs at least through the next 12 months. It expects continued substantial spending on LINZESS, pipeline development and potential external opportunities; no specific revenue or earnings guidance was provided.
- LINZESS pediatric functional-constipation Phase III results were positive. An sNDA for patients aged 6–17 was submitted in December 2022; in February 2023, FDA granted priority review with a June 14, 2023 PDUFA date. Approval was not assured. IW-3300 completed Phase I, with Phase II patient dosing in IC/BPS expected to begin in early 2023. COUR was conducting the CNP-104 PBC study, with early T-cell-response data expected in the second half of 2023.
- Principal business risks include dependence on LINZESS and AbbVie, pricing and reimbursement pressure, competition, clinical and regulatory uncertainty, and reliance on partners and third parties for manufacturing and commercialization. The company reported that COVID-19 had not significantly disrupted U.S. LINZESS supply as of the filing, while noting continuing potential effects on demand, field activity and trials.
- Five generic manufacturers had settled patent disputes and may launch generic LINZESS as early as March 2029, subject to FDA approval and specified conditions. The filing identifies U.S. linaclotide patents with expirations extending into the early 2030s, but patent challenges and other limits to protection remain risks.
- Other items to note: the 2021 earnings comparison is materially affected by the one-time tax valuation-allowance release; 2022 tax expense was largely non-cash. The company reported no material legal proceedings and received unqualified audit opinions on its financial statements and internal controls.
Important facts for investors to verify
- LINZESS prescription demand, net pricing, channel inventories and AbbVie-reported collaboration costs, which determine a substantial share of revenue and profit.
- Remaining convertible-note principal, conversion and settlement terms, and the company’s ability to fund the 2024 and 2026 maturities.
- FDA’s decision and timing for the pediatric FC application, and clinical progress and readouts for IW-3300 and CNP-104.
- Generic-entry timing, patent outcomes, reimbursement developments and any changes in supply or collaboration-partner execution.
- Use and realizability of deferred tax assets and carryforwards, including ownership-change limitations and the effect of future tax provisions on reported earnings.